XI3 Stock Overview
Engages in the development of stem cell-based biopharmaceuticals for veterinary use. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bioceltix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł15.08 |
| 52 Week High | zł19.80 |
| 52 Week Low | zł11.74 |
| Beta | 1.58 |
| 11 Month Change | 1.62% |
| 3 Month Change | -0.66% |
| 1 Year Change | 8.49% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 89.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| XI3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.5% | -1.1% | 1.1% |
| 1Y | 8.5% | -18.8% | 7.2% |
Return vs Industry: XI3 exceeded the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: XI3 exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| XI3 volatility | |
|---|---|
| XI3 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XI3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: XI3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 28 | Lukasz Bzdzion | bioceltix.com |
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
Bioceltix S.A. Fundamentals Summary
| XI3 fundamental statistics | |
|---|---|
| Market cap | €88.04m |
| Earnings (TTM) | -€3.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-24.2x
P/E RatioIs XI3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XI3 income statement (TTM) | |
|---|---|
| Revenue | zł0 |
| Cost of Revenue | zł1.38m |
| Gross Profit | -zł1.38m |
| Other Expenses | zł14.27m |
| Earnings | -zł15.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XI3 perform over the long term?
See historical performance and comparison